Budesonide/formoterol - Orion
Alternative Names: Bufomix EasyhalerLatest Information Update: 21 Oct 2021
At a glance
- Originator Orion
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Bronchodilators; Ethanolamines; Glucocorticoids; Pregnenediones; Small molecules
- Mechanism of Action Beta 2 adrenergic receptor agonists; Steroid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 06 Feb 2019 Launched for Chronic obstructive pulmonary disease in Germany (Inhalation) before February 2019
- 13 Feb 2017 Budesonide/formoterol licensed to Hikma Pharmaceuticals in the Middle-East and North Africa for the treatment of Asthma and Chronic obstructive pulmonary disease
- 02 Sep 2016 Orion and Menarini agree to co-promote in Germany, Italy, Spain, and Portugal for Asthma and Chronic obstructive pulmonary disease